Cancer Letters
Volume 224, Issue 1 , Pages 117-121 , 16 June 2005

Absence of epidermal growth factor receptor exon 18–21 mutation in hepatocellular carcinoma

  • Min-Cheng Su

      Affiliations

    • Department of Pathology, Min-Sheng General Hospital, 168, Ching-Kuo Road, Taoyuan City, Taiwan, ROC
    • ,
  • Huang-Chun Lien

      Affiliations

    • Department of Pathology, National Taiwan University Hospital and College of Medicine, National Taiwan University, 7, Chung-Shan South Road, Taipei, Taiwan, ROC
    • ,
  • Yung-Ming Jeng

      Affiliations

    • Department of Pathology, National Taiwan University Hospital and College of Medicine, National Taiwan University, 7, Chung-Shan South Road, Taipei, Taiwan, ROC
    • Corresponding Author InformationCorresponding author. Tel.: +886 2 23123456x5863; fax: +886 2 23934172.

Received 30 August 2004 ,Revised 5 October 2004 ,Accepted 7 October 2004.

References 

  1. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J. Clin. Gastroenterol. 2002;35:S72–S78
  2. Sturm JW, Keese M. Multimodal treatment of hepatocellular carcinoma (HCC). Onkologie. 2004;27:294–303
  3. Treiber G. Systemic treatment of hepatocellular carcinoma. Dig. Dis. 2001;19:311–323
  4. Johnson PJ. Are there indications for chemotherapy in hepatocellular carcinoma?. Surg. Oncol. Clin. N. Am. 2003;12:127–134
  5. Johnson PJ. Systemic chemotherapy of liver tumors. Semin. Surg. Oncol. 2000;19:116–124
  6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  7. Marchini S, D'Incalci M, Broggini M. New molecules and strategies in the field of anticancer agents. Curr. Med. Chem. Anti-Cancer Agents. 2004;4:247–262
  8. Hu B, Wei YQ. Tumor biotherapy based on epidermal growth factor receptor as a target. Ai Zheng. 2004;23:471–475
  9. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer. 2001;37:9–15
  10. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000;6:2053–2063
  11. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 2000;6:4885–4892
  12. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J. Am. Med. Assoc. 2003;290:2149–2158
  13. Parra HS, Cavina R, Latteri F, Zucali PA, Campagnoli E, Morenghi E, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer. Br. J. Cancer. 2004;91:208–212
  14. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500
  15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004;350:2129–2139
  16. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai Pl, Peng SY. ß-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol. 2000;157:763–770
  17. Peng SY, Lai PL, Chu JS, Lee PH, Tsung PT, Chen DS, et al. Expression and hypomethylation of α-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology. 1993;17:35–41
  18. Hsu HC, Chiou TJ, Chen JY, Lee CS, Lee PH, Peng SY. Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology. 1991;13:923–928
  19. Gresik EW, Kashimata M, Kadoya Y, Yamashina S. The EGF system in fetal development. Eur. J. Morphol. 1998;36:92–97
  20. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 2004;319:1–11
  21. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001;2:127–137
  22. Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification—rearrangement in human glioblastomas. Int. J. Cancer. 1995;62:145–148
  23. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer. 2001;84:1377–1383
  24. Zhao YN, Cao J, Wu FX, Ou C, Yuan WP, Mo QG, et al. Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma. Ai Zheng. 2004;23:762–766
  25. Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D'Errico A, et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig. Liver Dis. 2003;35:332–338
  26. Ranson M, Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J. Clin. Pharm. Ther. 2004;29:95–103
  27. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 2002;20:3815–3825
  28. Zhu BD, Yuan SJ, Xu JM, Zhao QC, Li X, Li Y, et al. The effect of IRESSA on H22 mouse hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi. 2004;84:684–686
  29. Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol. Cancer Ther. 2003;2:557–561
  30. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003;21:4342–4349
  31. Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clin. Leadersh. Manag. Rev. 2003;17:333–340

PII: S0304-3835(04)00800-6

doi: 10.1016/j.canlet.2004.10.010

Cancer Letters
Volume 224, Issue 1 , Pages 117-121 , 16 June 2005

Article Tools

* Image Usage & Resolution